AstraZeneca: Chinese government approves Tagrisso

(CercleFinance.com) - AstraZeneca today announced that its drug Tagrisso (osimertinib) has been approved in China as an adjuvant treatment for patients with certain non-small cell lung cancers (EGFRm) whose tumours have exon 19 deletions or exon 21 mutations (L858R).


The approval from China's National Medical Products Administration (NMPA) follows positive results from a Phase III trial.

"This approval reinforces the importance of EGFR testing across all stages of lung cancer, prior to treatment decisions, to ensure as many patients as possible can benefit from targeted therapies like Tagrisso and live cancer-free longer," said Dave Fredrickson, executive vice president of the Oncology Business Unit.


Copyright (c) 2021 CercleFinance.com. All rights reserved.